Goldman Sachs analyst Richard Law lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $29 and keeps a Neutral rating ...

Goldman Sachs has dropped an entire section dedicated to "diversity and inclusion" from its annual filing released on ...

Goldman Sachs Group Inc. erased diversity targets from a key regulatory filing, becoming the latest Wall Street firm to turn ...

In recent quarters, funding to companies in the legal and legal tech sectors has surged to levels comparable to what we saw ...

Goldman Sachs, which has been vocal about public commitments to diversity and inclusion, is shifting its stance, pointing to ...

Matt Levine is a Bloomberg Opinion columnist. A former investment banker at Goldman Sachs, he was a mergers and acquisitions lawyer at Wachtell, Lipton, Rosen & Katz; a clerk for the U.S. Court of ...

Robinson Bradshaw, one of Charlotte's largest law firms, is kicking off its 65th year in business with a major change.

Goldman Sachs is betting big on Dallas, Texas. Five employees, from partner to analyst, share what living and working there ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands against the other oversold ...

Goldman Sachs raised its 12-month price forecast for Europe's STOXX 600 index on Friday, citing the potential benefits of a peace deal between Russia and Ukraine for the region's equities. The ...

1MDB asset recovery taskforce chairman Johari Ghani said the lack of clarity in the Putrajaya-Goldman Sachs agreement is allowing ... said the suspension of a law banning bribery of foreign ...